Endonovo Therapeutics, Inc.
Income Statement
| Line Item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $135.4K | $73.1K | $165.8K | $310.2K | $83.3K | $4.3K | $24.2K | $22.9K |
| Cost of Revenue | $10.0K | $15.0K | $65.4K | $93.4K | $12.9K | $2.2K | $15.5K | $14.0K |
| Gross Profit | $125.4K | $58.1K | $100.4K | $216.8K | $70.3K | $2.1K | $8.7K | $8.9K |
| Gross Margin | 92.6% | 79.5% | 60.6% | 69.9% | 84.5% | 49.3% | 36.0% | 38.9% |
| Operating Expenses | ||||||||
| Research & Development | — | $0 | $3.3K | $153.1K | $274.3K | — | — | — |
| SG&A Expense | — | — | — | — | — | — | — | — |
| Operating Income | $-3.3M | $-2.2M | $-2.9M | $-3.8M | $-4.2M | $-2.6M | $-2.2M | $-2.4M |
| Operating Margin | -2,411.7% | -3,045.7% | -1,756.5% | -1,228.1% | -4,995.3% | -60,132.7% | -9,057.6% | -10,607.6% |
| Interest Expense | — | $941.6K | $2.1M | $17.0K | — | — | — | — |
| Pretax Income | $-18.5M | $-3.1M | $-395.6K | $-17.3M | $-6.4M | $-6.8M | $-959.5K | $-2.9M |
| Income Tax Expense | — | — | — | — | — | $0 | $0 | $532 |
| Net Income | $-18.5M | $-3.1M | $-395.6K | $-17.3M | $-6.4M | $-6.8M | $-959.5K | $-2.9M |
| Net Margin | -13,649.2% | -4,247.2% | -238.6% | -5,582.4% | -7,729.5% | -158,633.9% | -3,966.2% | -12,634.5% |
| EPS (Basic) | $-0.13 | $-0.03 | $-0.02 | $-12.42 | $-8.88 | $-0.04 | $-0.02 | $-1.98 |
| EPS (Diluted) | — | $-0.03 | $-0.02 | $-12.42 | $-8.88 | $-0.04 | $-0.02 | $-1.98 |
| Shares Outstanding (Basic) | 139.2M | 119.7M | 49.1M | 2.4M | 862.1M | 209.6M | 162.9M | 1.7M |
| Shares Outstanding (Diluted) | 139.2M | 119.7M | 49.1M | 2.4M | 862.1M | 209.6M | 162.9M | 1.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |